Sarepta Therapeutics (SRPT) Common Equity (2010 - 2026)
Sarepta Therapeutics (SRPT) posted quarterly Common Equity of $1.5 billion for Q1 2026, up 31.71% year-over-year from $1.1 billion in Q1 2025, and up 31.95% quarter-over-quarter from $1.1 billion in Q4 2025.
Sarepta Therapeutics (SRPT) Common Equity (2010 - 2026) Analysis & Trends
Sarepta Therapeutics' Common Equity history runs 17 years deep, the most recent figure standing at $1.5 billion for Q1 2026.
- In Q1 2026, Common Equity rose 31.71% year-over-year to $1.5 billion; the TTM figure through Mar 2026 stood at $1.5 billion (up 31.71% YoY), while the FY2025 annual figure was $1.1 billion, down 25.34% from the prior year.
- Common Equity for Q1 2026 stood at $1.5 billion, up from $1.1 billion in the prior quarter.
- The five-year high for Common Equity was $1.5 billion in Q4 2024, with the low at $385.0 million in Q4 2022.
- The 5-year median for Common Equity is $961.2 million (2024), against an average of $984.1 million.
- The sharpest annual moves came in 2022 and 2023: Common Equity plunged 58.52% in 2022, then jumped 123.23% in 2023.
- Sarepta Therapeutics' Common Equity stood at $385.0 million in 2022, then jumped by 123.23% to $859.3 million in 2023, then surged by 77.78% to $1.5 billion in 2024, then fell by 25.34% to $1.1 billion in 2025, then soared by 31.95% to $1.5 billion in 2026.
- Business Quant data shows SRPT's Common Equity at $1.5 billion in Q1 2026, $1.1 billion in Q4 2025, and $1.3 billion in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 20.25 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 31.71 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.61 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 5.17 Bn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 8.57 Mn |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 9.79 Bn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 1.35 Bn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 757.49 Mn |
| 10 | Sarepta Therapeutics | 1.91 Bn | 1.12 Bn | 251.87 Mn | 1.53 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 1.53 Bn |
| Mar 31, 2026 | 1.51 Bn |
| Dec 31, 2025 | 1.14 Bn |
| Sep 30, 2025 | 1.32 Bn |
| Jun 30, 2025 | 1.36 Bn |
| Mar 31, 2025 | 1.14 Bn |
| Dec 31, 2024 | 1.53 Bn |
| Sep 30, 2024 | 1.22 Bn |
| Jun 30, 2024 | 1.08 Bn |
| Mar 31, 2024 | 961.19 Mn |
| Dec 31, 2023 | 859.34 Mn |
| Sep 30, 2023 | 764.36 Mn |
| Jun 30, 2023 | 741.41 Mn |
| Mar 31, 2023 | 712.75 Mn |
| Dec 31, 2022 | 384.95 Mn |
| Sep 30, 2022 | 430.84 Mn |
| Jun 30, 2022 | 726.46 Mn |
| Mar 31, 2022 | 856.89 Mn |
| Dec 31, 2021 | 928.01 Mn |
| Sep 30, 2021 | 469.53 Mn |